Prognostic value of CD103+ tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinoma-Reference-Cited by-同舟云学术

Prognostic value of CD103+ tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinoma

Published:2022-12 Issue: Volume:135 Page:106226
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Smith Joshua D.,Bellile Emily L.,Ellsperman Susan E.,Heft-Neal Molly E.,Mann Jacqueline E.,Birkeland Andrew C.,Hoesli Rebecca C.,Swiecicki Paul L.,Worden Francis P.,Schonewolf Caitlin,Shah Jennifer L.,Mierzwa Michelle L.,Rosko Andrew J.,Stucken Chaz L.,Chinn Steven B.,Shuman Andrew G.,Casper Keith A.,Malloy Kelly M.,Prince Mark E.P.,Wolf Gregory T.,Thomas Dafydd G.,McHugh Jonathan B.,Chad Brenner J.,Spector Matthew E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference31 articles.

1. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study;Cohen;Lancet,2019

2. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial;Sacco;Lancet Oncol,2021

3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label, phase 3 study;Burtness;Lancet,2019

4. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study;Bauml;J Clin Oncol,2017

5. Immunotherapy for head and neck cancer: recent advances and future directions;Cramer;Oral Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Oncology;2024-07-26

2. Intratumoral CD103⁺CD8⁺ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma;Cancer Communications;2023-09

3. Association between radiomics features of DCE-MRI and CD8+ and CD4+ TILs in advanced gastric cancer;Pathology and Oncology Research;2023-06-05

4. Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma;Diagnostics;2023-02-23